Drug Shortage Report for APO-DABIGATRAN
Report ID | 142272 |
Drug Identification Number | 02468913 |
Brand name | APO-DABIGATRAN |
Common or Proper name | DABIGATRAN |
Company Name | APOTEX INC |
Market Status | MARKETED |
Active Ingredient(s) | DABIGATRAN ETEXILATE |
Strength(s) | 150MG |
Dosage form(s) | CAPSULE |
Route of administration | ORAL ORAL |
Packaging size | 60 BTL |
ATC code | B01AE |
ATC description | ANTITHROMBOTIC AGENTS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2021-07-06 |
Estimated end date | |
Actual end date | 2022-10-06 |
Shortage status | Resolved |
Updated date | 2022-10-07 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 150 SIGNET DRIVE TORONTO, ONTARIO CANADA M9L 1T9 |
Company contact information | Apotex Customer Service - 1-877-427-6839 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v11 | 2022-10-07 | English | Compare |
v10 | 2022-10-06 | French | Compare |
v9 | 2022-10-06 | English | Compare |
v8 | 2021-10-07 | French | Compare |
v7 | 2021-10-07 | English | Compare |
v6 | 2021-09-03 | French | Compare |
v5 | 2021-09-03 | English | Compare |
v4 | 2021-07-29 | French | Compare |
v3 | 2021-07-29 | English | Compare |
v2 | 2021-07-09 | French | Compare |
v1 | 2021-07-09 | English | Compare |
Showing 1 to 11 of 11